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not use quality-adjusted life years (QALYs) in its efficiency frontier approach to
pharmacoeconomic evaluation. The lack of a global measure of effectiveness
across indications is subject to criticism by international experts. In response,
IQWiG refers to German legal restrictions. The objective of this analysis is to ex-
amine whether German legislation allows the use of QALYs in pharmacoeconomic
evaluation.METHODS:We employ a legal analysis of German legislation concern-
ing the provisions relevant to pharmacoeconomic analysis by IQWiG. Our analysis
includes specific pharmacoeconomic provisions, constitutional restrictions and
jurisdiction. RESULTS: According to German Social Code Book V, IQWiG’s phar-
macoeconomic evaluation is to be based on international standards. This could
hint at the NICE’s use of QALYs if the existence of an international standard is
assumed in the first place. The Federal Constitutional Court of Germany, however,
has consistently stressed life and health as most important fundamental rights in
the German constitution. German jurisdiction has interpreted the German consti-
tution as prohibiting putting amonetary value on life or health. However, the global
use of QALYswould imply putting an explicit or implicit threshold value on aQALY,
i.e. a value on life and health. Therefore, IQWiG’s reluctance to use QALYs in its
method is justified by legal restrictions as imposed by the German constitution.
CONCLUSIONS: Our analysis shows that English standards cannot be adopted
without considering legal restrictions in the German context. These restrictions
prohibit the use of QALYs. The use of QALYs is motivated by the assumption of a
fixed health care budget. The German legislator confirmed its rejection of this
assumption by increasing Statutory Health Insurance contributions from 14.9 % to
15.5 %, effective January 2011.
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OBJECTIVES: Analysis of pharmacoeconomic studies (FES), held in the Republic of
Kazakhstan between 2005 and 2010. METHODS: Produced an information search
using keywords pharmacoeconomics, clinical and economic analy-
sis. It was analyzed 81 scientific researches of national researchers which was
published in the republican (national) publications. RESULTS: Among the papers
was dominated pharmacoeconomic studies (FES) in the therapeutic (bronchial
asthma, COPD, hypertension, peptic ulcer, etc.) and psychiatric practice (mostly -
Pharmacoeconomics of neuroleptics). Studies of the clinical and economic aspects
for health technology assessments are not found. Selection of FES carried proac-
tive. Among the methods of pharacoeconomic analysis (FEA) the most frequently
used analysiswascost of disease. Cost-effectiveness analysiswas used in 23
(28%) studies. Incremental analysis was performed only in 2 FES. Analysis of the
costminimizationwas usedmethodologically correct only in 2 papers.Mod-
eling in the FES was used in 10 (12%) studies. Another 6 (0.7%) works extrapolated
the results of foreign researchers, taking into account the national clinical practice.
Others were presented reviews of popularization of pharmacoeconomics, ABC and
VEN-analysis of various medical organizations. CONCLUSIONS: In Republic of Ka-
zakhstan pharmacoecnomics is at an early stage of development. There is a need to
update and deploy the FES on the background of the proper use themethodology of
pharmacoeconomics, the definition of a coordinator and a real consumer FES, im-
provement of legislation provision for such research.
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OBJECTIVES: Quality of life (QoL) information is increasingly used in research. This
pilot study evaluated the feasibility of collecting electronic QoL data in UK general
practices that can be linked to patients’ anonymous electronic medical records.
METHODS: Patients18 years who visited one of three practices contributing data to
The Health Improvement Network (THIN) database during a 31-day period were in-
cluded. Patients were asked to complete an experimental electronic questionnaire
based on the EQ5D questionnaire and EQ5Dvas (Visual Analogue Scale) on a personal
digital assistant (PDA) (PocketVision, Inchware).Datawereanalysedandeachpractice
was interviewedshortly after studyend for feedback.Acceptability ratewasdefinedas
thepatients completing thequestionnairedividedby thepatientsasked toparticipate;
feasibility rate was the proportion of visiting patients asked to participate. RESULTS:
In total, 177 of 5058 visiting patients, were asked to participate with mean age 47.6
years (standard deviation (SD):17.7) versus 51.6 years (SD:19.0) (p-value0.003) for pa-
tients not asked (n4881). The overall acceptability rate was 93.2% (164/176, one pa-
tient excluded as recorded as both accepted and declined). Mean age for patients
completing the questionnaire was 47.0 years (SD:17.3) versus 51.0 years (SD:17.1) for
patients declining (p-value0.447). There was no difference between genders. The
overall feasibility rate was 3.5%(177/5058): 10.1%(94/929) for Practice-1, 1.1%(16/1529)
for Practice-2, 2.6%(67/2600) for Practice-3. Practices suggested that multiple PDAs
could have been helpful and it was time-consuming to monitor the PDA; however,
they preferred the electronic method over paper questionnaires and were happy to
repeat the experiment. CONCLUSIONS: The high acceptability rate suggests that pa-
tients are prepared to provide electronicQoL data. Thismay also be owing to practices
targeting younger patientswho appearmore familiarwith electronic devices. Though
feasibility ratesdifferedacrosspractices, allwerewilling to takepart again, supporting
electronic QoL data collection.
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OBJECTIVES: Naïve Bayesian networks are used in syndromic surveillance to clas-
sify emergency department chief complaints into disease syndromes and detect
outbreaks in an automated real-time manner. Study objectives were to develop a
modified Bayesian classifier and compare its performance to the naïve Bayesian
classifier. METHODS: Data from the Real-time Outbreak and Disease Surveillance
(RODS) system containing 1000 chief complaints were classified into one of 8 syn-
drome classifications (Gastrointestinal, Constitutional, Respiratory, Rash, Hemor-
rhagic, Botulinic, Neurological, and Other) by a physician. All algorithms in the
studywere comparedwith this standard. The datawere used to develop, train, and
test the naïve and modified Bayesian networks. For each chief complaint, the syn-
drome classification was predicted by using all other chief complaints in the data
set to train the Bayesian network and calculate prior probabilities. Multinomial
logistic regression (MNL) and Classification and Regression Trees (CART) models
were also examined to provide benchmark measures of performance. Kappa sta-
tistics and p-values were calculated. RESULTS: The data set contained only 1 chief
complaint for the Botulinic syndrome, which was consequently excluded from the
study. The remaining 999 chief complaints and 7 syndrome classifications were
used to develop and estimate the models. To simplify the statistical analysis, 68
chief complaints with more than one classification were excluded, resulting in a
total of 931 chief complaints. Kappa statistics for the naive Bayesian network
(©0.85), modified Bayesian network (©0.85), CART (©0.83) and MNL
(©0.86) indicate that all classifiers perform similarly compared to expert classi-
fication (p 0.01 for all kappa statistics). CONCLUSIONS: All methods performed
similarly, suggesting that choice of algorithm in syndrome classification does not
really matter. The CART approach may be preferred over the Bayesian or logistic
approaches as it is rule-based and, therefore, can be easily implemented in virtu-
ally any electronic health record system.
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OBJECTIVES: To demonstrate that differential discounting can confuse comparisons
of cost-effectiveness between interventions. In particular, to show that directly com-
paring cost-effectiveness ratios of different interventions from conventional cost-ef-
fectiveness models can result in misleading cost-effectiveness rankings under differ-
ential discounting. METHODS: A simple example of a comparison of the cost-
effectiveness of two hypothetical interventions is used. The first intervention is a
once-off vaccination, which imposes costs in one year alone per patient-cohort. The
second intervention is a therapy for a chronic condition, which imposes costs for
many consecutive years per patient-cohort. Both interventions are assessed on the
conventional basis of a single cohort of patients, resulting in cost-effectiveness esti-
mates for each intervention, which are then compared. An alternative comparison of
cost-effectiveness is then made; it considers the opportunity cost of adopting the
therapy for one cohort of patients in terms of the vaccination that could be provided
for many cohorts over the same period. This alternative comparison yields a second
pair of cost-effectiveness ratios which are compared to those from the conventional
per cohort comparison. RESULTS: Comparing the interventions on the basis of the
actual opportunity cost with the same distribution of spending over time shows the
vaccination to be relatively more cost-effective than under the conventional per co-
hort analysis. Furthermore, the alternative comparison shows the two interventions
to have the same relative cost-effectiveness as if the conventional per cohort compar-
ison had been undertaken with discount rates unadjusted for growth in the cost-
effectiveness threshold (equal discounting). CONCLUSIONS: The debate over differ-
ential discounting has not considered the practical implications for decision making.
Our analysis shows that accounting for threshold growth using differential discount-
ing can make comparisons from conventional forms of cost-effectiveness analysis
misleading as to which interventions are most cost-effective. Accounting for thresh-
old growth using differential discounting is less relevant for decision making than
previously understood.
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OBJECTIVES: To develop an instrument to assess usefulness of any given simulation
software in theHealth Economics (HE) field and to create a list of available software for
modeling.METHODS: A continued Internet search for available open source or com-
mercial discrete events simulation (DES) software that could be used in the HE field
was performed for four years. Selection of packages included in this study was based
either in having animation or amodule based programming or becausemodels could
beuploaded andaccessed through Internet. Amoredetailed comparison (building the
same model) was made between TreeAge ProSuite, Arena-Basic, Simul8-Basic and
Simul8-Professional with an instrument designed by the author specifically for this
reason including 22 items grouped in three categories: 1) Processing capacity and ease
of use; 2) Adaptability to HE; 3) Transparency and capacity to self-explain. Other pack-
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